BioCryst Pharmaceuticals (NASDAQ:BCRX) has iniated a phase 1 trial of the anti-viral Galidesivir in Brazil with funding from the NIAID.
Altimmune will develop the vaccine, AdCOVID, with University of Alabama at Birmingham, UAB, scientists to prepare for Phase 1 trials in Q3.
The Nature study detailed S309, an antibody providing potent protection against SARS coronaviruses and COVID-19 further developed by Vir.
iBio has expanded its COVID-19 vaccine production capacity by partnering with the NIIMBL and could produce 500 million doses annually.
Heat Biologics is finalizing completion of their COVID-19 vaccine and plans to initiate pre-clinical testing and apply for funding in Q2.
COVID-19 vaccine mRNA-1273 demonstrated safety and immunogenicity in a phase 1 trial. Moderna expects a phase 3 trial to start in July 2020.
Everything that you should know about the progress of the Novavax coronavirus vaccine towards phase 3 human trials: latest news and timeline.